Yifan Pharmaceutical Co Ltd
SZSE:002019
EV/GP
Enterprise Value to Gross Profit
Market Cap | EV/GP | ||||
---|---|---|---|---|---|
CN |
Y
|
Yifan Pharmaceutical Co Ltd
SZSE:002019
|
16.6B CNY | 8.4 | |
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -164 697 976 | |
US |
Eli Lilly and Co
NYSE:LLY
|
766.1B USD | 27.3 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
4.1T DKK | 20 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 1 026 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
363.1B USD | 6.2 | ||
US |
Merck & Co Inc
NYSE:MRK
|
331.4B USD | 7.8 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
191.7B GBP | 61.6 | ||
CH |
Roche Holding AG
SIX:ROG
|
188B CHF | 4.7 | ||
CH |
Novartis AG
SIX:NOVN
|
183.5B CHF | 4.8 | ||
US |
Pfizer Inc
NYSE:PFE
|
161.4B USD | 5.6 |
EV/GP Forward Multiples
Forward EV/GP multiple is a version of the EV/GP ratio that uses forecasted gross profit for the EV/GP calculation. 1-Year, 2-Years, and 3-Years forwards use gross profit forecasts for 1, 2, and 3 years ahead, respectively.